Serum Paraoxonase Activity and Phenotype Distribution in Covid-19 Patients

Year 2024, Volume: 6 Issue: 2, 62 - 66, 05.09.2024

Halil İsa Çelik , Şahabettin Selek , Ertan Sönmez , Hüseyin Metin , Bahadir Taslidere , Bedia Gülen

https://doi.org/10.55994/ejcc.1282938

Abstract

Objective: For the phenotype classification, it is important to determine the relationship between enzyme activity and the severity of the COVID-19 disease. Reaching significant differences between healthy and infected individuals in terms of genotype and allele distributions may be a guide in the fight against the COVID-19 pandemic. This study, it was aimed to investigate the relationship between serum arylesterase PON1 enzyme activity and disease severity in COVID-19 patients.
Methods: Patients over the age of 18 who applied to the Emergency Service between 01-30 April 2020 and were examined with a preliminary diagnosis of COVID-19 were included in the study. In the study, serum PON1 activity was measured in the venous blood of 56 patients diagnosed with Covid-19 disease by either CT or RT-PCR and who have not received any systemic treatment yet.
Results: The Arylesterase (AREase) and Paraoxonase (POase) activity levels of the study and control groups were 131.49 ± 52.75 kU/L 142.29 ± 38.82 kU/L, 276.48 ± 220.4 U/L 505.30 ± 301.4 U/L, respectively. It was found that 64.3 % of those infected with Covid-19 had the low-activity PON1 phenotype (p= 0.007)
Conclusion: Genetic variability in PON1 may be associated with exposure to or risk of developing the disease. As a result, vaccination of individuals with low activity phenotype can be given priority at the vaccination stage in order to reduce the mortality rate in the fight against the pandemic. Awareness and protection measures of societies with low activity phenotypes can be increased.

Keywords

Phenotype, COVİD-19, Paraoxonase

Supporting Institution

yok

References

• 1. Nabatchian F, Ashtiani M, Davoudi M, Teimourpour A, Davoudi N. A Multivariate Analysis Model of Changes in Some labıratory Paameters in Response to COVİD-19, Diabetes, Gender, and Age. Clin Lab. 2021 Aug 1;67(8). doi: 10.7754/Clin.Lab.2021.210106.
• 2. SA Lauer, KH Grantz, Q Bi, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med (2020), 10.7326/M20-0504
• 3. C Huang, Y Wang, X Li, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet, 395 (2020), pp. 497-506, 10.1016/S0140-6736(20)30183-5
• 4. Bhopal SS, Bhopal R. Sex differential in COVID-19 mortality varies markedly by age. Lancet. 2020 Aug 22;396(10250):532-533. doi: 10.1016/S0140-6736(20)31748-7. Epub 2020 Aug 13. PMID: 32798449
• 5. Sahebkar, A. Hernández-Aguilera, A. Abelló,et all. Systematic review and meta-analysis deciphering the impact of fibrates on paraoxonase-1 status. Metabolism-Clinical and Experimental 65, 609–622, 2016. DOI: http://dx.doi.org/10.1016/j.metabol.2016.01.002
• 6. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473–80.
• 7. Campbell LA, Rosenfeld ME. Infection and Atherosclerosis Development. Arch Med Res. 2015 Jul;46(5):339-50. doi: 10.1016/j.arcmed.2015.05.006. Epub 2015 May 21.
• 8. Y. H. Jin, L. Cai, and Z. S. Cheng, “A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019- nCoV) infected pneumonia (standard version),” Military Medical Research, vol. 7, no. 4, 2020. 9. www. relassay.com (Gaziantep, TURKEY) 10. Selek S, Cosar N, Kocyigit A, et al. PON1 activity and total oxidant status in patients with active pulmonary tuberculosis. Clinical Biochemistry 2008; 41: 140- 4.
• 11. Pasqualini L, Cortese C, Marchesi S, et al. Paraoxonase-1 activity modulates endothelial function in patients with peripheral arterial disease. Atherosclerosis 2005; 183: 349-54.
• 12. Aslan M, Kosecik M, Horoz M, et all. Assessment of paraoxonase and arylesterase activities in patients with iron defi ciency anemia. Atherosclerosis 2007; 191: 397-402
• 13. Kalkan-Yazıcı, M. M. M. Koc, N. S. Cetin, et all. Discordance between Serum Neutralizing Antibody Titers and the Recovery from Coronavirus Disease 2019. Accepted for publication. J. Immunology
• 14. X. Xie, Z. Zhong, W. Zhao et al., “Chest CT for typical 2019- nCoV pneumonia: relationship to negative RT-PCR testing,” Radiology, p. 200343. In press, 2020.
• 15. Suhail S, Zajac J, Fossum C, et all. Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. Protein J. 2020 Dec;39(6):644-656. doi: 10.1007/s10930-020-09935-8. Epub 2020 Oct 26.
• 16. Clement E. Furlong, Judit Marsillach, Gail P. Jarvik, et all. Paraoxonases-1, -2 and -3: What are their Functions? Chem Biol Interact. Author manuscript; available in PMC 2017 Nov 25.
• 17. Maryam Sotoudeh Anvari, Maryam Mortazavian Babaki, Mohammad Ali Boroumand, et all. Relationship between calculated total antioxidant status and atherosclerotic coronary artery disease. Anatol J Cardiol. 2016 Sep; 16(9): 689–695.
• 18. S W van den Berg, E H J Jansen, M Kruijshoop, et all. Paraoxonase 1 phenotype distribution and activity differs in subjects with newly diagnosed Type 2 diabetes (the CODAM Study). Diabet Med. 2008 Feb; 25(2):186-93.
• 19. Mirdamadi HZ, Sztanek F, Derdak Z, et all. The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters. J Clin Pharmacol. 2008 Sep; 66(3):366-74. 20. Ashiq S, Ashiq K. The Role of Paraoxonase 1 (PON1) Gene Polymorphisms in Coronary Artery Disease: A Systematic Review and Meta-Analysis. Biochem Genet. 2021 Aug;59(4):919-939. doi: 10.1007/s10528-021-10043-0. Epub 2021 Feb 18.
• 21. Rios DL, D'Onofrio LO, Cerqueira CC, et all. Paraoxonase 1 gene polymorphisms in angiographically assessed coronary artery disease: evidence for gender interaction among Brazilians. Clin Chem Lab Med. 2007; 45(7):874-8.